Mirtazapine
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Mirtazapine: From Major Depressive Disorder to Ohdo Syndrome and Variants
One-Sentence Summary
Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA), publicly known for treating Major Depressive Disorder; formal Taiwan/NZ regulatory indication text is not available in this evidence pack. The TxGNN model predicts potential relevance to Ohdo syndrome and variants, a rare congenital chromosomal-developmental disorder, but this prediction is currently supported by 0 clinical trials and 0 publications — it rests entirely on network-embedding similarity with no mechanistic or empirical corroboration.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Major Depressive Disorder (MDD) — based on general pharmacological knowledge; formal regulatory indication text not provided in evidence pack |
| Predicted New Indication | Ohdo syndrome and variants |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 |
| New Zealand Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known general pharmacology, mirtazapine acts via α2-adrenergic receptor antagonism and 5-HT2/5-HT3 receptor blockade plus H1 antihistamine activity, an action profile established for major depressive disorder.
Ohdo syndrome and its variants are rare autosomal-dominant congenital disorders, most commonly linked to mutations in KAT6A/KAT6B or other SET-domain-related developmental genes. These are structural/developmental gene disorders, not disorders of monoaminergic neurotransmission — there is no established biological pathway connecting mirtazapine's receptor pharmacology to Ohdo syndrome's genetic-developmental etiology.
Per the model's own repurposing rationale, this association reflects TxGNN network-embedding similarity only, with no known biological or mechanistic link identified. Two related predictions (blepharophimosis–intellectual disability syndrome, Ohdo type; and benign paroxysmal torticollis of infancy) share the same limitation — the latter has a marginally more plausible theoretical tie to serotonergic/noradrenergic dysregulation (as a migraine-variant syndrome), but still lacks any supporting study. This prediction should be treated as a hypothesis-generation signal only, not a mechanistically substantiated candidate.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This is an L5 (model-prediction-only) candidate with no clinical trials, no literature, and no identifiable mechanistic pathway linking mirtazapine's known pharmacology to Ohdo syndrome's genetic-developmental pathology. There is no basis to advance to safety or clinical evaluation at this time.
To proceed, the following is needed:
- TFDA/regulatory package insert (warnings, contraindications) — currently a blocking data gap (DG001)
- Confirmed mechanism of action and original indication documentation (DG002)
- Preclinical or mechanistic studies exploring any plausible biological link between mirtazapine's receptor targets and Ohdo syndrome pathophysiology
- Any case reports or observational data, should they emerge, given the current complete absence of trials/literature
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.